GlassScriptPhysician profile
Saqib Masood
NPI 1467447805
$1,982.45
in general payments reported to CMS, 2019-2025
23 companies · $313 in 2025
The $313 reported for 2025 was more than what 86% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $67.18 · 2021: $467 · 2022: $401 · 2023: $304 · 2024: $178 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $275.48 | 2021-2025 | Qelbree, Qelbree |
| Abbott Laboratories | $243.08 | 2021-2022 | |
| Corium, LLC | $195.85 | 2022-2024 | Azstarys |
| Cranial Technologies, INC | $175.96 | 2019-2025 | Doc Band |
| Baxter Healthcare | $117.60 | 2022 | |
| Merck Sharp & Dohme LLC | $111.61 | 2019-2025 | Vaxneuvance, Gardasil 9, Enflonsia |
| Takeda Pharmaceuticals U.S.A., INC. | $102.45 | 2019-2021 | |
| Pfizer INC. | $92.59 | 2020-2025 | |
| Tris Pharma INC | $92.28 | 2022-2025 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $90.38 | 2019-2024 | Bexsero, Fluarix Quadrivalent |
| Ironshore Pharmaceuticals INC. | $76.10 | 2019-2023 | Jornay Pm |
| Sanofi Pasteur INC. | $58.11 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $54.82 | 2022-2024 | Crysvita |
| Vertical Pharmaceuticals, LLC | $54.44 | 2019 | |
| Lilly USA, LLC | $50.64 | 2022-2023 | Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lifescan, INC. | $48.84 | 2021 | |
| Adlon Therapeutics L.P. | $37.72 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $21.10 | 2025 | Jornay Pm |
| Ironwood Pharmaceuticals, INC | $20.45 | 2024 | |
| Sanofi-Aventis U.S. LLC | $17.67 | 2025 | |
| Alk-Abello, INC | $15.40 | 2025 | Grastek, Odactra, Ragwitek |
| Neos Therapeutics, LP | $15.17 | 2019 | |
| Seqirus USA INC | $14.71 | 2025 | Flucelvax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saqib Masood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.